Literature DB >> 3409458

Cardiopulmonary hemodynamics and pharmacokinetics after hepatic intraarterial infusion of 5-fluorouracil (5-FU). An experimental study in the pig.

M Andersson1, L Domellöf, S Häggmark, G Johansson, S Reiz, B Gustavsson.   

Abstract

Reported 5-FU-induced cardiac side effects may be explained by drug-induced hemodynamic changes and/or by direct myocardial toxicity due to regional drug uptake. This question was studied in 11 animals given constant infusions and 6 animals given bolus 5-FU infusions into the hepatic artery. Six animals, which received normal saline infusion, served as controls. A second aim was to study possible pulmonary drug clearance. Aortic, pulmonary arterial, and coronary sinus plasma 5-FU concentrations were determined during constant and after the bolus infusions of 5-FU. The V5 ECG, aortic, pulmonary arterial, and right atrial pressures were recorded continuously, and cardiac output and coronary sinus blood flow were recorded intermittently in all animals. No significant alterations in hemodynamic variables were seen during constant infusion. After the bolus infusion, an increased arterio-mixed venous oxygen content difference was recorded. Pharmacokinetic data after 3-min infusions indicated pulmonary drug uptake and release; during constant infusions, the data indicated myocardial drug uptake. As there were no alterations in myocardial oxygen demand or supply or in systemic hemodynamics during this myocardial drug uptake, it is likely that the cardiotoxicity is related to the direct effects of the drug on cardiac myocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409458     DOI: 10.1007/bf00273420

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

1.  Five years clinical experience with 5-fluorouracil.

Authors:  F J ANSFIELD; J M SCHROEDER; A R CURRERI
Journal:  JAMA       Date:  1962-07-28       Impact factor: 56.272

2.  Letter: Cardiotoxicity of 5-fluorouracil (NSC-19893)

Authors:  A Roth; K Kolaric; S Popovic
Journal:  Cancer Chemother Rep       Date:  1975 Nov-Dec

3.  New developments on the mechanisms of action of antineoplastic drugs.

Authors:  R C Donehower; C E Myers; B A Chabner
Journal:  Life Sci       Date:  1979-07-02       Impact factor: 5.037

4.  Augmentation by thymidine of the incorporation and distribution of 5-fluorouracil in ribosomal RNA.

Authors:  C K Carrico; R I Glazer
Journal:  Biochem Biophys Res Commun       Date:  1979-04-13       Impact factor: 3.575

5.  5-FU cardiotoxicity.

Authors:  S Sanani; M B Spaulding; A R Masud; R Canty
Journal:  Cancer Treat Rep       Date:  1981 Nov-Dec

6.  Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man.

Authors:  O E Almersjö; B G Gustavsson; C G Regårdh; P Wåhlén
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980-05

7.  Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.

Authors:  T M Woodcock; D S Martin; L A Damin; N E Kemeny; C W Young
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

8.  Regional and systemic serum concentrations of 5-fluorouracil after portal and intravenous infusion: an experimental study in dogs.

Authors:  B G Gustavsson; A Brandberg; C G Regårdh; O E Almersjö
Journal:  J Pharmacokinet Biopharm       Date:  1979-12

9.  Differential depressant and electrophysiologic cardiotoxicity of local anesthetics: an experimental study with special reference to lidocaine and bupivacaine.

Authors:  S Nath; S Häggmark; G Johansson; S Reiz
Journal:  Anesth Analg       Date:  1986-12       Impact factor: 5.108

10.  Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes.

Authors:  J M Collins; R L Dedrick; F G King; J L Speyer; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

View more
  1 in total

Review 1.  Cardiotoxicity of the antiproliferative compound fluorouracil.

Authors:  K Becker; J F Erckenbrecht; D Häussinger; T Frieling
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.